Cardio-Renal-Metabolic Research
Read about our patient-centric approach to cardio-renal-metabolic disease research.
Search
Phase II trial results in people living with obesity or overweight
Phase II trial with BI 456906 met primary endpoint after 46 weeks of treatment, representing an important advancement of Boehringer Ingelheim’s cardio-renal-metabolic focus areas
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
It’s Your Heart. Protect It. The Podcast.
In season 2, we hear from a range of experts to explore further how the interconnected systems call for collaboration and approach to care.
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
Promising phase II results in chronic kidney disease
Boehringer Ingelheim’s investigation of novel compound on top of standard of care empagliflozin shows promising results for chronic kidney disease
Anti-fibrotic agent
Anti-fibrotic agent
NPY2r agonist
Food intake regulator
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Connect the Docs
Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
Survodutide (BI 456906)
Survodutide (BI 456906)
Avenciguat (BI 685509)
Avenciguat (BI 685509)
BI 765845
Heart disease modulator
Survodutide (BI 456906)
BI 456909
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
2020 European PRRS Research Award sponsorship
2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
Research Beyond Borders Partnering
Our Research Beyond Borders team is looking for emerging science and technology opportunities. Learn more about partnering with us.
Winners of the 2020 European PRRS Research Award
Winners of the 2020 European PRRS Research Award announced Three winner awarded 25,000 euro each for their research.
2021 PRRS Research Award winners announced
The 2021 European PRRS Research Award winners announced
Oncology and Cancer Immunology Research
Find out more about our research and development in oncology and cancer immunology.
Winners of the 2019 European PRRS Research Award
Winners of the 2019 European PRRS Research Award announced.
Research ruminant animal health well-being
Boehringer Ingelheim supports young scientists and veterinarians dedicated to ruminant health research
Immunology Respiratory Research
Find out more about our research and development in Immunology & Respiratory diseases
Research Beyond Borders overview
Learn more about how our Research Beyond Borders team is uncovering new ideas and new science.